Response of VEGF and AT-II to HCG in PCOS
The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women With Polycystic Ovary Syndrome
1 other identifier
interventional
60
0 countries
N/A
Brief Summary
This research is to investigate the response of vascular active factors, vascular endothelial growth factor (VEGF) and angiotensin-Ⅱ (AT-Ⅱ) to ovary stimulation during 24h in patients with polycystic ovary syndrome (PCOS).Controled prospective clinical study involved 60 women undergoing in vitro fertilization. Fifty-two patients with PCOS and 8 control cases were stimulated with human chorionic gonadotropin (HCG) during the early follicular phase of the menstrual cycle (4st to 7th days of the cycle).The blood was sampled before the injection (0 hour) and at the 3, 6, 12, 18 and 24 hours points after the stimulation. VEGF, AT-Ⅱ were measured by radioimmunoassay.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for early_phase_1
Started Jan 2010
Typical duration for early_phase_1
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2010
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2012
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2012
CompletedFirst Submitted
Initial submission to the registry
October 3, 2014
CompletedFirst Posted
Study publicly available on registry
October 16, 2014
CompletedOctober 16, 2014
October 1, 2014
2.4 years
October 3, 2014
October 10, 2014
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Levels of vascular endothelial growth factor(VEGF) and angiotensin-Ⅱ(AT-Ⅱ)
24 hours
Study Arms (4)
Group 1
EXPERIMENTALtypical PCOS
Group 2
EXPERIMENTALPCOS without PCO
Group 3
EXPERIMENTALPCOS without HA
Group 4
EXPERIMENTALControl
Interventions
Eligibility Criteria
You may qualify if:
- A total of 60 women were recruited and divided into four groups by Rotterdam criteria according to three typical characters:
- biochemical characteristics of hyperandrogenism (HA)
- chronic anovulation
- polycystic ovary morphology (PCO).
You may not qualify if:
- All women were matched for age (\<35 yr).
- All subjects were screened, and no other endocrine disturbances (thyroid, adrenal) or medical illnesses were found.
- All the patients did not have any hormonal preparation during the 3 months preceding the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Related Publications (1)
Qu J, Che Y, Xu P, Xia Y, Wu X, Wang Y. The Higher Response of Vascular Endothelial Growth Factor and Angiotensin-II to Human Chorionic Gonadotropin in Women with Polycystic Ovary Syndrome. Int J Fertil Steril. 2015 Jan-Mar;8(4):373-8. doi: 10.22074/ijfs.2015.4176. Epub 2015 Feb 7.
PMID: 25780518DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- early phase 1
- Allocation
- NON RANDOMIZED
- Masking
- NONE
- Purpose
- BASIC SCIENCE
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate Professor
Study Record Dates
First Submitted
October 3, 2014
First Posted
October 16, 2014
Study Start
January 1, 2010
Primary Completion
June 1, 2012
Study Completion
December 1, 2012
Last Updated
October 16, 2014
Record last verified: 2014-10